SPOTLIGHT: Baxter, Chiron win H5N1 contract

The UK's Department of Health has handed a £33 million contract to Baxter and Chiron for the delivery of 3.5 million doses of H5N1 vaccine. The vaccine will be used for research and possibly to inoculate front line workers in the event of a pandemic as researchers scramble to produce an exact vaccine for any mutation that may occur. Report

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.